iRegene Therapeutics is a biotechnology company headquartered in Wuhan, China, with additional facilities in Suzhou. The firm specializes in regenerative medicine and advanced cell therapies designed to redefine modern medicine.
Subscribe to see iRegene’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
iRegene is a drug discovery company headquartered in Wuhan, China. Its most recent funding round, Series B+, raised $42.1M in September 2025. Xcout tracks 1 named person at iRegene, including Jun Wei (Founder and CEO).
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B+ | $42.1M | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of iRegene's closest competitors — see the full list of competitors and alternatives →
Rege Nephro Co., Ltd. is a biotechnology company headquartered at Kyoto University in Kyoto, Japan. The company engages in medical-pharmaceutical collaborative research and advanced therapeutic development for kidney and regenerative medicine.
Vivacta Biotechnology is a biopharmaceutical company headquartered in Shanghai, China, specializing in innovative biotechnology research. The company is focused on developing in vivo CAR-T therapies utilizing a targeted delivery system.
LUCA Science is a pre-clinical stage biotechnology company that develops functional mitochondria as therapeutic agents to treat damaged tissues and organs. The company utilizes a proprietary method to isolate functional mitochondria, combining it with advanced drug delivery and formulation technology to create storable biopharmaceutical agents.
Kringle Pharma, Inc. is a late-stage regenerative drug discovery bio-venture located in Shinsenrihigashimachi, Osaka, Japan. The company operates in the biotechnology and manufacturing sectors.
Founded in 2021 and headquartered in Shenzhen, China, MagicRNA Biotechnology Co., Ltd. is a clinical-stage biotechnology company focused on nucleic acid drug delivery and the research and development of next-generation mRNA and lipid nanoparticle technologies for the treatment of cancer and infectious diseases.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about iRegene? Suggest a correction · Work at iRegene? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.